Evommune, Inc. (EVMN)
| Market Cap | 480.14M |
| Revenue (ttm) | 10.00M +233.3% |
| Net Income | -94.67M |
| EPS | -4.15 |
| Shares Out | 36.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 350,567 |
| Open | 13.48 |
| Previous Close | 13.48 |
| Day's Range | 12.97 - 13.65 |
| 52-Week Range | 10.47 - 33.20 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 27.63 (+108.84%) |
| Earnings Date | Aug 6, 2026 |
About EVMN
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Financial Performance
In 2025, Evommune's revenue was $13.00 million, an increase of 85.71% compared to the previous year's $7.00 million. Losses were -$68.87 million, 0.82% more than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for EVMN stock is "Buy." The 12-month stock price target is $27.63, which is an increase of 108.84% from the latest price.
News
Evommune initiated with a Buy at Needham
Needham initiated coverage of Evommune (EVMN) with a Buy rating and $28 price target Evommune has a “promising I&I pipeline,” notably EVO301, which has demonstrated proof-of-concept efficacy on par or...
Evommune price target lowered to $29 from $30 at RBC Capital
RBC Capital lowered the firm’s price target on Evommune (EVMN) to $29 from $30 and keeps an Outperform rating on the shares. Despite the stock’s recovery from lows, shares remain…
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Slides: Corporate presentation
Evommune has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Evommune Quarterly report: Q2 2026
Evommune has published its Q2 2026 quarterly earnings report on August 6, 2026.
Evommune Earnings release: Q2 2026
Evommune released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Evommune initiates Phase 2b trial of EVO756
Evommune (EVMN) announced the first patient was dosed in its Phase 2b clinical trial evaluating EVO756, for the prophylactic treatment of migraine. “Initiating this migraine trial is an exciting miles...
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
PALO ALTO, Calif., & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key driver...
Evommune participates in a conference call with Cantor
Cantor holds a conference call with management on July 31 at 11:30 am hosted by Cantor.Webcast Link
Clear Street sees attractive point into Evommune after selloff
Clear Street views the recent selloff in shares of Evommune (EVMN) as creating an attractive entry point with the Phase 2b atopic dermatitis data for EVO756 expected in Q3. Positive…
Septerna price target lowered to $45 from $52 at Guggenheim
Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Septerna (SEPN) to $45 from $52 and keeps a Buy rating on the shares after Evommune (EVMN) announced top-line results…
Evommune price target lowered to $26 from $55 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Evommune (EVMN) to $26 from $55 and keeps an Overweight rating on the shares after the failure of its lead asset, EVO756,…
Evommune downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor downgraded Evommune (EVMN) to Neutral from Buy without a price target after EVO756 failed to meet the Phase 2b primary endpoint. This is “materially damaging”…
Evommune price target lowered to $28 from $53 at Clear Street
Clear Street lowered the firm’s price target on Evommune (EVMN) to $28 from $53 and keeps a Buy rating on the shares after the company announced that the Phase IIb…
Evommune downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Evommune (EVMN) to Market Perform from Outperform without a price target after the company announced that the Phase IIb study of EVO756 in chronic spontaneous urticaria failed...
Evommune announces Phase 2b trial of EVO756 did not meet primary endpoint
Evommune (EVMN) announced top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in ...
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street
Clear Street reiterated a Buy rating and $53 price target on Evommune (EVMN), saying Abbvie’s (ABBV) proposed acquisition of Apogee (APGE) provides a positive readthrough to Evommune’s pipeline. In pa...
Evommune Transcript: AGM 2026
The meeting covered the election of two directors and ratification of the independent auditor, with both proposals approved. No shareholder questions were submitted, and voting results will be reported on Form 8-K within four business days.
Evommune price target raised to $55 from $54 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Evommune (EVMN) to $55 from $54 and keeps an Overweight rating on the shares.
Evommune reports Q1 EPS (64c), consensus (71c)
“We continue to make meaningful progress across our broad chronic inflammation targeted pipeline and remain on track to deliver top-line Phase 2b data for EVO756 in CSU in June and…
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Quarterly report: Q1 2026
Evommune has published its Q1 2026 quarterly earnings report on May 7, 2026.
Evommune Earnings release: Q1 2026
Evommune released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Evommune Slides: Corporate presentation
Evommune has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.